These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27776922)

  • 41. Use of mirror dystonia as guidance for injection of botulinum toxin in writing dysfunction.
    Singer C; Papapetropoulos S; Vela L
    J Neurol Neurosurg Psychiatry; 2005 Nov; 76(11):1608-9. PubMed ID: 16227568
    [No Abstract]   [Full Text] [Related]  

  • 42. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
    Dowson AJ; Kilminster SG; Salt R
    Drugs R D; 2008; 9(3):147-58. PubMed ID: 18457467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ultrasound-Guided OnabotulinumtoxinA Injections to Treat Oromandibular Dystonia in Cerebral Palsy.
    Reyes FI; Shoval HA; Tenaglia A; Kim H
    Toxins (Basel); 2022 Feb; 14(3):. PubMed ID: 35324655
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up.
    Tan EK; Jankovic J
    Neurology; 1999 Dec; 53(9):2102-7. PubMed ID: 10599789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson's disease.
    Santamato A; Ranieri M; Panza F; Zoccolella S; Frisardi V; Solfrizzi V; Amoruso MT; Amoruso L; Fiore P
    J Neurol; 2010 Jan; 257(1):139-41. PubMed ID: 19763384
    [No Abstract]   [Full Text] [Related]  

  • 47. Efficacy of botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: experience of the Botulinum Toxin Outpatients Department.
    Tomić A; Vujović B; Svetel M; Misković ND; Petrović I; Pekmezović T; Kostić VS
    Vojnosanit Pregl; 2015 Dec; 72(12):1069-73. PubMed ID: 26898029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oromandibular dystonia revisited: a review and a unique case.
    Balasubramaniam R; Rasmussen J; Carlson LW; Van Sickels JE; Okeson JP
    J Oral Maxillofac Surg; 2008 Feb; 66(2):379-86. PubMed ID: 18201628
    [No Abstract]   [Full Text] [Related]  

  • 49. Botulinum toxin in motor disorders.
    Bentivoglio AR; Albanese A
    Curr Opin Neurol; 1999 Aug; 12(4):447-56. PubMed ID: 10555834
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of onabotulinum toxin type A injections in patients with Meige's syndrome.
    Duarte A; Coutinho L; Germiniani FMB; Teive HAG
    Arq Neuropsiquiatr; 2024 Apr; 82(4):1-7. PubMed ID: 38641339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A.
    Tan SR; Solish N
    Dermatol Surg; 2002 Jun; 28(6):495-9. PubMed ID: 12081678
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Somatosensory input and oromandibular dystonia.
    Møller E; Bakke M; Dalager T; Werdelin LM; Lonsdale MN; Højgaard L; Friberg L
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1141-3. PubMed ID: 23036658
    [No Abstract]   [Full Text] [Related]  

  • 53. Multidisciplinary management of a partially edentulous patient with oromandibular dystonia: A clinical report.
    Sakar O; Matur Z; Mumcu Z; Sesen P; Oge E
    J Prosthet Dent; 2018 Aug; 120(2):173-176. PubMed ID: 29429838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.
    Kessler KR; Skutta M; Benecke R
    J Neurol; 1999 Apr; 246(4):265-74. PubMed ID: 10367694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral appliances in the treatment of oromandibular dystonia: a systematic review.
    De Meyer M; Vereecke L; Bottenberg P; Jacquet W; Sims AB; Santens P
    Acta Neurol Belg; 2020 Aug; 120(4):831-836. PubMed ID: 32594465
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment with botulinum toxin injections does not change brainstem interneuronal excitability in patients with cervical dystonia.
    Valls-Sole J; Tolosa ES; Marti MJ; Allam N
    Clin Neuropharmacol; 1994 Jun; 17(3):229-35. PubMed ID: 9316668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Chinese girl with Leigh syndrome: effect of botulinum toxin on dystonia.
    Leung TF; Hui J; Yeung WL; Goh K
    J Paediatr Child Health; 1998 Oct; 34(5):480-2. PubMed ID: 9767517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia.
    Ansved T; Odergren T; Borg K
    Neurology; 1997 May; 48(5):1440-2. PubMed ID: 9153487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument.
    Müller J; Wissel J; Kemmler G; Voller B; Bodner T; Schneider A; Wenning GK; Poewe W
    J Neurol Neurosurg Psychiatry; 2004 May; 75(5):749-53. PubMed ID: 15090572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Basis of movement control in dystonia and why botulinum toxin should influence it?
    Wagle Shukla A
    Toxicon; 2024 Jan; 237():107251. PubMed ID: 37574115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.